Why Did INmune Bio Plunge 28.63%?

On May 9, 2025, INmune Bio experienced a significant drop of 28.63% in pre-market trading, indicating a substantial shift in investor sentiment towards the biotechnology company.

INmune Bio's short interest ratio has been a notable factor, with 5.98 million shares shorted, representing 41.62% of the float. This high level of short interest suggests that a significant portion of the market is betting against the company, which could contribute to the recent price decline.

In the latest earnings call, INmune Bio reported Q1 2025 revenue of $50,000. While this figure may seem modest, it is important to consider the context of the company's operations and its focus on research and development. The earnings call provided insights into the company's financial health and strategic direction, which could influence investor decisions.

Renaissance Technologies LLC has increased its holdings in INmune Bio by 73.3% in the fourth quarter, indicating a bullish stance on the company's prospects. This institutional investment could provide some support to the stock, despite the recent decline. However, the overall market sentiment remains cautious, as reflected in the high short interest ratio.